谷胱甘肽S-transferase A1多态性和急性graft-vs。宿主疾病在hla兄弟同种异体造血干细胞移植。

文章的细节

引用

复制到剪贴板

金我Keam B,李KH, Kim JH哦SY, Ra EK, Yoon党卫军,公园党卫军,金正日CS,公园,香港YC BK

谷胱甘肽S-transferase A1多态性和急性graft-vs。宿主疾病在hla兄弟同种异体造血干细胞移植。

移植手术。2007;3 - 4月21(2):207 - 13所示。

PubMed ID

17425746 (在PubMed

]

文摘

白消安和环磷酰胺的代谢物与谷胱甘肽共轭酶和异化的胞质谷胱甘肽S-transferases家庭。显然有联系单核苷酸多态性在谷胱甘肽S-transferase A1基因的启动子区域(即。,GSTA1 *, -567 t, -69 c和-52克;GSTA1 * B, -567克,-69 t, -52)。我们评估是否临床结果,包括急性graft-vs。宿主疾病、血液恶性肿瘤患者的61后hla兄弟同种异体干细胞移植使用白消安/环磷酰胺调节受谷胱甘肽S-transferase A1基因型的影响而改变。在全球范围内,年级II-IV急性graft-vs。宿主疾病开发的13个病人(21%)。年级II-IV急性graft-vs。宿主疾病开发了15.2%的患者46 GSTA1 * / * diplotype和40.0%的患者15 GSTA1 * / * B或GSTA1 * / * B diplotype (p = 0.04)。此外,这种关系GSTA1 * / * diplotypes和急性graft-vs发病率更低。宿主疾病是独立于年龄、性别、干细胞来源,和疾病状态。 The incidences of acute skin graft-vs.-host disease were 7% (3/46) in patients with GSTA1*A/*A and 27% (4/15) in patients without GSTA1*A/*A (p = 0.009, univariate; p = 0.01, multivariate). Acute hepatic graft-vs.-host disease developed in 6 (13%) of 46 patients with the GSTA1*A/*A diplotype and in 4 (27%) of 15 patients without this diplotype (p = 0.09, univariate; p = 0.12, multivariate). Ten patients (16%) developed hepatic veno-occlusive disease. No significant difference was found in the incidence of hepatic veno-occlusive disease between patients with and without the GSTA1*A/*A diplotype (19.6% vs. 6.7%; p = 0.24). We conclude that the GSTA1*A/*A diplotype is an independent protective factor against acute graft-vs.-host disease, especially for skin graft-vs.-host disease, and probably for hepatic graft-vs.-host disease, in patients using busulfan/cyclophosphamide conditioning. The identification of glutathione S-transferase A1 genotypes prior to allogeneic stem cell transplantation could allow conditioning regimens and graft-vs.-host disease prophylaxis to be modified to improve outcome.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
谷胱甘肽	谷胱甘肽S-transferase A1	蛋白质	人类	未知的	不可用	细节